INT145594

From wiki-pain
Revision as of 02:42, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2011
Negated 3
Speculated 1
Reported most in Body
Documents 64
Total Number 72
Disease Relevance 35.33
Pain Relevance 30.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mtx1)
Anatomy Link Frequency
plasma 2
ADAL 2
joint 1
blood 1
gut 1
Mtx1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 3345 100.00 Very High Very High Very High
Etanercept 1256 100.00 Very High Very High Very High
Adalimumab 185 100.00 Very High Very High Very High
Arthritis 1428 99.80 Very High Very High Very High
Infliximab 385 99.76 Very High Very High Very High
rheumatoid arthritis 780 99.70 Very High Very High Very High
Pain 497 99.50 Very High Very High Very High
fibrosis 30 99.44 Very High Very High Very High
withdrawal 69 99.12 Very High Very High Very High
Osteoarthritis 87 98.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 1397 100.00 Very High Very High Very High
Adverse Drug Reaction 159 99.98 Very High Very High Very High
Ciguatera Poisoning 222 99.92 Very High Very High Very High
Juvenile Chronic Polyarthritis 972 99.80 Very High Very High Very High
Toxicity 293 99.80 Very High Very High Very High
Disease 828 99.78 Very High Very High Very High
Arthritis 445 99.54 Very High Very High Very High
Pain 450 99.50 Very High Very High Very High
Cirrhosis 10 99.44 Very High Very High Very High
Recurrence 33 99.34 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Relationship between blood MTX level and toxicity
Gene_expression (level) of MTX in blood associated with toxicity and methotrexate
1) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.46 Pain Relevance 0.62
Present status of MTX therapy for JIA in Japan
Gene_expression (therapy) of MTX associated with methotrexate and arthritis
2) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 1.07 Pain Relevance 0.53
Another factor making this an urgent issue is that biological preparations indicated for JIA have already been approved in Western countries and have been clinically reported to alleviate arthritis more markedly than is expected of MTX.
Gene_expression (expected) of MTX associated with methotrexate and arthritis
3) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.95 Pain Relevance 0.69
Since MTX is expected to be effective in about 85% of multiple-joint type JIA cases, it is used as the first-line drug.
Gene_expression (expected) of MTX in joint associated with methotrexate and arthritis
4) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 1.24 Pain Relevance 1.18
There was no difference in the MTX dose or plasma MTX level between responders (15 cases) and nonresponders (seven cases) or between those with (15 cases) and without (seven cases) elevated serum transaminase levels.
Gene_expression (dose) of MTX in plasma associated with methotrexate
5) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.55 Pain Relevance 0.97
M/L, higher than the known toxic range of MTX (over 0.1 ?
Gene_expression (range) of MTX associated with methotrexate
6) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.72 Pain Relevance 0.61
Regarding the known hepatotoxicity of MTX in adults with RA, minute attention should be paid when MTX is used for children.
Gene_expression (used) of MTX associated with rheumatoid arthritis, hepatotoxicity and methotrexate
7) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 1.42 Pain Relevance 0.85
They additionally stated that when using MTX for children, it should be taken into account that pharmacokinetics vary depending on age.


Gene_expression (using) of MTX associated with methotrexate
8) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.44 Pain Relevance 0.60
However, no significant change was noted in MTX clearance (10.6 ± 5.5 vs. 13.1 ± 3.5 L/h, P = 0.19), AUC (2.1 ± 1.0 ?
Gene_expression (clearance) of MTX associated with methotrexate
9) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.35 Pain Relevance 1.32
There was no difference in the MTX dose or plasma MTX level between responders (15 cases) and nonresponders (seven cases) or between those with (15 cases) and without (seven cases) elevated serum transaminase levels.
Gene_expression (level) of MTX in plasma associated with methotrexate
10) Confidence 0.57 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.45 Pain Relevance 0.94
The primary endpoint for all PROs was comparison of mean improvement from baseline to week 16 between ETN and ETN+MTX groups.
Gene_expression (groups) of MTX
11) Confidence 0.51 Published 2008 Journal Ann. Rheum. Dis. Section Body Doc Link 17666447 Disease Relevance 0.26 Pain Relevance 0
MTX responder: defined as patients who fulfilled three criteria—physician statement of good response and ESR ?
Gene_expression (responder) of MTX associated with methotrexate
12) Confidence 0.50 Published 2008 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2468887 Disease Relevance 0.23 Pain Relevance 0.38
Regardless of age or disease subtype, considerable interindividual variability in clinical response and adverse reactions exists with MTX, and thus far, there have been no predictive variables for outcomes in patients taking this medication.
Gene_expression (exists) of MTX associated with adverse drug reaction, disease and methotrexate
13) Confidence 0.46 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.52 Pain Relevance 0.28
After controlling for MTX dose, subjects with higher proportions of MTXglu1+2??
Gene_expression (dose) of MTX associated with methotrexate
14) Confidence 0.46 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.18 Pain Relevance 0.32
Higher concentrations of MTXglu1+2 were observed in patients receiving oral doses of MTX, whereas higher concentrations of MTXglu3-5 were observed in patients receiving subcutaneous doses of MTX (P <.0001), even after correcting for dose.
Gene_expression (doses) of MTX associated with methotrexate
15) Confidence 0.46 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.28 Pain Relevance 0.29
Future areas of study in this area may include investigating the developmental expression of tissue specific transporters, which may explaining the higher rate of subcutaneous administration and the higher doses of MTX used in children compared to adults.
Spec (investigating) Gene_expression (expression) of MTX associated with methotrexate
16) Confidence 0.41 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.22 Pain Relevance 0.13
CONCLUSION: Our findings of a non-normal distribution of 7-OH-MTX excretion suggest that there are at least 2 phenotypes for this catabolism.
Gene_expression (excretion) of MTX
17) Confidence 0.36 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0 Pain Relevance 0
Relatively high 7-OH-MTX excretion was correlated with relatively high MTX excretion and with relatively low MTX retention in vivo (P<0.05) (n=35).
Gene_expression (excretion) of MTX
18) Confidence 0.36 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.06 Pain Relevance 0
Patients who received folic acid supplements had decreased 7-OH-MTX excretion (P=0.03).
Gene_expression (excretion) of MTX
19) Confidence 0.36 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.06 Pain Relevance 0
Relatively high 7-OH-MTX excretion was correlated with relatively high MTX excretion and with relatively low MTX retention in vivo (P<0.05) (n=35).
Gene_expression (excretion) of MTX
20) Confidence 0.36 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox